Azilsartan

Drug Profile

Azilsartan

Alternative Names: Azilva; TAK-536

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Developer Lees Pharmaceutical Holdings; Takeda
  • Class Antihypertensives; Benzimidazoles; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Essential hypertension

Most Recent Events

  • 01 Jun 2016 Takeda initiates a phase III trial for Hypertension (In adolescents, In children) in Japan (PO, Tablet and Granules) (JapicCTI-163260)
  • 25 May 2016 Lee's Pharmaceutical plans a phase pharmacokinetics I trial in Healthy volunteers in China (PO) (NCT02786082)
  • 03 Feb 2016 Takeda completes a phase III trial in Hypertension (In children, In adolescents) in Japan (NCT02451150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top